Chen Wang

Dr. Chen Wang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
QWQingpeng Wang
Qingpeng Wang
JCJiangyang Chi
Jiangyang Chi
CWChen Wang
Chen Wang
YYYun Yang
Yun Yang
RTRui Tian
Rui Tian
XCXinzhong Chen
Xinzhong Chen
Objective: The aim of this study is to assess the association between epicardial adipose tissue (EAT) and coronary artery disease (CAD) via meta−analysis. Methods: Specific searches of online databases from January 2000 to May 2022 were conducted. All observational studies evaluating the association between EAT and CAD in PubMed, Web of Science, and the Cochrane Library databases were screened. A meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta−Analyses guidelines (PRISMA). In total, 21 studies encompassing 4975 subjects met the inclusion criteria, including 2377 diagnosed and assigned as the CAD group, while the other 2598 were assigned as the non−CAD group. Subjects in the CAD group were further divided into the severe stenosis group (stenosis ≥ 50%, n = 846) and the mild/moderate stenosis group (stenosis < 50%, n = 577). Results: Both the volume and thickness of EAT in the CAD group were larger compared to the non−CAD group (p < 0.00001). In a subgroup analysis within the CAD group, the severe stenosis group had a larger volume and thickness with respect to EAT when compared to the mild/moderate group (p < 0.001). Conclusions: The enlargement of EAT presented in CAD patients with an association with CAD severity. Although limited by different CAD types and measuring methods for EAT, as well as a smaller sample size, our results suggest that EAT is a novel predictor and a potential therapeutic target for CAD.

Verified
Journal Article
Open access
PDF file
CWChen Wang
Chen Wang
YJYefan Jiang
Yefan Jiang
QWQingpeng Wang
Qingpeng Wang
RTRui Tian
Rui Tian
DWDashuai Wang
Dashuai Wang
XCXinzhong Chen
Xinzhong Chen
Introduction: No previous studies comparing the outcomes between off-pump coronary artery bypass grafting (off-pump CABG, OPCAB) and on-pump CABG (ONCAB) have been performed in patients with severe left ventricular dysfunction (LVD) and a giant left ventricle. We aimed to investigate whether such patients could benefit from OPCAB. Methods: From January 2011 to January 2021, a total of 98 patients with severe LVD and a giant left ventricle underwent isolated CABG (ONCAB 46, OPCAB 52) in Wuhan Union Hospital. The clinical data were collected retrospectively and propensity score matching was performed to adjust baseline characteristics. Results: After propensity matching, the two groups were comparable in baseline variables. The OPCAB group had a higher rate of incomplete revascularization than the ONCAB group (25.0% vs. 9.1%; p = 0.047). The 30-day mortality was similar between the matched groups (4.5% vs. 4.5%; p = 1.000) but the OPCAB group had a lower risk of postoperative IABP usage (9.1% vs. 25.0%; p = 0.047) and renal insufficiency (11.4% vs. 29.5%; p = 0.034). The long-term probability of survival (log-rank test, p = 0.450) was similar between the two groups but the OPCAB group had a lower probability of major adverse cardiovascular events (log-rank test, p = 0.038). Conclusions: For patients with severe LVD and a giant left ventricle, OPCAB reduced early postoperative complications while sacrificing long-term quality of life compared to those having ONCAB.

17 November 2026 in Circulation
Verified
Journal Article
Open access
JFJing Fang
Jing Fang
YCYue Chen
Yue Chen
WZWei Zhou
Wei Zhou
RLRui Li
Rui Li
CGChaoyu Gong
Chaoyu Gong
XWXiang Wei
Xiang Wei
BACKGROUND: Nonobstructive hypertrophic cardiomyopathy (nHCM), defined as hypertrophic cardiomyopathy without left ventricular outflow tract obstruction, remains challenging to treat because of its heterogeneous pathophysiology. This study evaluated the safety and efficacy of transapical beating-heart septal myectomy in patients with symptomatic nHCM. METHODS: Patients with symptomatic, drug-refractory nHCM were prospectively enrolled to undergo transapical beating-heart septal myectomy through a left minithoracotomy. Under real-time transesophageal echocardiographic guidance, septal myectomy was tailored to relieve systolic cavity obliteration and mid-to-apical ventricular obstruction and to enlarge the left ventricular cavity. The primary end point was procedural success at 6 to 12 months postoperatively, defined as fulfillment of all prespecified criteria compared with baseline: ≥1-class improvement in New York Heart Association functional class, ≥10-point increase in Kansas City Cardiomyopathy Questionnaire score, ≥10-mL increase in stroke volume, and normal or grade I diastolic function. RESULTS: Between January 2023 and January 2025, 97 consecutive eligible patients with nHCM underwent transapical beating-heart septal myectomy at Tongji Hospital. At postoperative 6 to 12 months, procedural success was achieved in 87.6%. Specifically, New York Heart Association functional class I increased from 0% at baseline to 93.8% at follow-up, the median Kansas City Cardiomyopathy Questionnaire score improved from 64 (interquartile range, 56–69) to 87 (interquartile range, 82–92; P <0.001), the stroke volume increased from 53.5 mL (interquartile range, 41.0–66.6 mL) to 70.8 mL (interquartile range, 61.3–82.3 mL; P <0.001), and normal or grade I diastolic function increased from 65.6% to 97.9%. Among patients who underwent paired cardiopulmonary exercise testing (n=58), peak oxygen uptake increased by 1.1±2.9 mL/kg/min ( P =0.008). In an exploratory, hypothesis-generating analysis of 12 patients with paired 1 3 N-ammonia positron emission tomography, coronary flow reserve increased from 1.8±0.3 to 2.0±0.4 ( P =0.034). Adverse events included mitral valve injury (n=1) and ventricular septal perforation (n=1), the latter resulting in 1 postoperative death. CONCLUSIONS: Transapical beating-heart septal myectomy was associated with favorable left ventricular geometric remodeling and meaningful improvements in symptoms, health status, and functional capacity in selected patients with symptomatic nHCM. Being a potential therapeutic option for a previously difficult-to-treat population, it warrants further evaluation in controlled, multicenter studies. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05648825.